Aprea Therapeutics
APRE
26 hedge funds and large institutions have $6.83M invested in Aprea Therapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
24% more capital invested
Capital invested by funds: $5.5M → $6.83M (+$1.33M)
18% more funds holding
Funds holding: 22 → 26 (+4)
1.33% more ownership
Funds ownership: 36.85% → 38.19% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$118K |
| 2 |
LPL Financial
San Diego,
California
|
+$53.6K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$43.5K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$40.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exome Asset Management
New York
|
-$30.8K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$4.46K |
| 3 |
NS
NBC Securities
Birmingham,
Alabama
|
-$2K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$167 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3 |
APRE Hedge Fund Activity: Q4 2024 in Review
26 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2024, worth a combined $6.83M — up 24% from $5.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new APRE positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Landscape Capital Management, opening a new position worth an estimated $118K. The largest seller was Exome Asset Management, cutting an estimated $30.8K.
- 26 institutional investors held Aprea Therapeutics (APRE) as of Q4 2024, up from 22 in Q3 2024.
- Funds reported $6.83M of Aprea Therapeutics stock for Q4 2024, up 24% quarter-over-quarter.
- 5 funds opened new Aprea Therapeutics positions in Q4 2024 and 1 closed out, a net change of +4 holders.
- The largest Aprea Therapeutics buyer in Q4 2024 was Landscape Capital Management, an estimated $118K added.
- The largest Aprea Therapeutics seller in Q4 2024 was Exome Asset Management, an estimated $30.8K sold.
Based on aggregated 13F filings for Q4 2024.